Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback